Page 9 - Greg Behar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Alec Mattinson2021-04-30T08:06:00+01:00 Top story Nestlé has boosted its presence in the global nutrition and supplement market with the US$5.75bn acquisition of The Bountiful Company. The company confirmed it has entered into an agreement with private equity investor KKR to buy the core brands of The Bountiful Company, which is says in the number one pure-play leader in its “highly attractive” sector. The transaction includes the high-growth brands Nature’s Bounty, Solgar, Osteo Bi-Flex and Puritan’s Pride as well as the company’s US private label business. These brands will ...

Vevey, Switzerland, Nestlé and KKR today have entered into an agreement in which Nestlé will acquire core brands of The Bountiful Company for USD 5.75 billion. The Bountiful Company is the number one pure-play leader in the highly attractive and growing global nutrition and supplement category. The transaction includes the high-growth brands Nature's Bounty®, Solgar®, Osteo Bi-Flex® and Puritan’s Pride® as well as the company's US private label business. These brands will be integrated into Nestlé Health Science, creating a global leader in vitamins, minerals and nutrit...

Sonova Holding AG: Sonova announces changes to its Board of Directors Sonova announces changes to its Board of Directors Stäfa (Switzerland), February 11, 2021 - Sonova Holding AG, a leading provider of hearing solutions, announces today that its Board of Directors has nominated Greg Behar and Roland Diggelmann as new Board members for election at the next Annual General Meeting (AGM) in June 2021. At the same time, Beat Hess, Vice Chair and member of the Board of Directors since 2012, will retire from his position for age reasons. In addition, Michael Jacobi will not stand for re-election a...

EU authorises Aimmune’s peanut allergy treatment Palforzia Approval in the EU comes nine months after US authorisation Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. The EC has approved Palforzia for use in children aged four to 17 with a confirmed diagnosis of a peanut allergy. The treatment must be accompanied by a diet that avoids peanuts. It is not intended for, and does not provide, immediate relief of allergic symptoms. In Europe, 17 million people are affected by food allergies, with a peanut allergy b...